%0 Journal Article
%T Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis.
%A Stahlie EHA
%A Mulder EEAP
%A Reijers S
%A Balduzzi S
%A Zuur CL
%A Klop WMC
%A van der Hiel B
%A Van de Wiel BA
%A Wouters MWJM
%A Schrage YM
%A van Houdt WJ
%A Grunhagen DJ
%A van Akkooi ACJ
%J Crit Rev Oncol Hematol
%V 175
%N 0
%D Jul 2022
%M 35569723
%F 6.625
%R 10.1016/j.critrevonc.2022.103705
%X Single-agent Talimogene Laherparepvec (T-VEC) was developed for treatment of unresectable and injectable stage III-IV melanoma. Since its approval and reimbursement, studies have reported varying response rates. The purpose of this systematic review and meta-analysis was to investigate the efficacy and safety of T-VEC. Of 341 publications that were identified, eight studies with a total of 642 patients were included. In patients with stage IIIB-IVM1a, the pooled complete- and overall response rate (CRR and ORR) were 41% and 64%, respectively. In patients with stage IIIB-IVM1c, the pooled CRR and ORR were 30% and 44%, respectively. In patients with stage IVM1b and IVM1c, the pooled CRR and ORR were 4% and 9%, respectively. Adverse events (AEs) were seen in 41-100% of all patients and 0-11% of AEs were severe. In conclusion, single agent T-VEC achieves the highest response rates in patients with early metastatic melanoma and is well-tolerated with generally only mild toxicities.